Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy

Table 1 Articles about targeted drugs plus sintilimab plus interventional therapy on hepatocellular carcinoma

Rank	Journal	Publication time	Title
1	World Journal of Clinical Cases	2024 January	Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma[3]
2	International Journal of Surgery	2023 May	TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study[4]
3	Liver International	2024 April	Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study[5]
4	Journal of Cancer Research and Clinical Oncology	2024 September	Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: A retrospective study[6]
5	Journal of Hepatology	2024 August	The efficacy and safety of radiofrequency ablation combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: A real-world study[7]
6	Journal of Hepatocellular Carcinoma	2023 April	A retrospective analysis of conversion therapy with lenvatinib, sintilimab, and arterially-directed therapy in patients with initially unresectable hepatocellular carcinoma[8]
7	Cancer Immunology, Immunotherapy	2024 November	Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: A real-world study[9]
8	Hepatology	2024 October	Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study[10]

TACE-HAIC: Transarterial chemoembolization-hepatic arterial infusion chemotherapy.